WGc-043

Overview

WGc-043 is an investigational mRNA therapeutic vaccine encoding EBV antigens (LMP1/LMP2/EBNA1). It is evaluated in EBV-positive recurrent/metastatic nasopharyngeal carcinoma (NPC).

Evidence in the corpus

• mRNA EBV vaccine WGc-043 in EBV+ R/M NPC (NCT05714748, n=12): ORR 16.7%; no grade ≥3 treatment-related adverse events PMID:24952746.

Resistance mechanisms

Cancer types (linked)

• NPC

Sources

This page was processed by entity-page-writer on 2026-05-11.